Where Peptide Compounding Rules Stand in 2026: BPC-157, FDA Categories and What's Pending

General information only. This content is not legal, tax, medical or regulatory advice, and reading it does not create an attorney-client, provider or advisory relationship with Melius Wellness LLC. Melius is a business and operational advisory firm, not a law firm, and does not provide legal services. Laws and regulations vary by state and change often, and this content may not reflect recent changes. Consult qualified healthcare counsel and your tax and clinical advisers before acting on it. Last reviewed: October 2026.

Current as of October 22, 2026. Rules are changing; check FDA for the latest.

Peptides such as BPC-157, TB-500 and KPV have had an unusually busy year in federal regulation. Headlines have described them as "approved," "legal again" or "rescheduled." None of those is accurate. This guide sets out what FDA has actually done, what is still pending, and the operational questions clinics, telehealth brands and management companies should be working through with their counsel and pharmacy partners.

Nothing in this guide is a statement about whether any peptide is safe or effective for any use. None of the peptides discussed here is an FDA-approved drug, and compounded drugs are not FDA-approved.

Summary: what changed in 2026

• April 15–22, 2026: twelve peptides left FDA's 503A "Category 2." FDA announced it would remove 12 peptides, including BPC-157, TB-500, KPV, MOTS-c, semax and epitalon, from Category 2 (bulk drug substances that raise significant safety risks) because the nominators had withdrawn their nominations. FDA's safety-risk page now lists them under a separate heading, "Bulk drug substances nominated but withdrawn," and still describes FDA's safety concerns for each. (FDA safety-risks page; Orrick, Apr. 16, 2026)
• Leaving Category 2 did not make them compoundable. Removal from Category 2 did not place these substances in Category 1 or on the 503A bulks list. Counsel commenting at the time described them as sitting in a "regulatory gray area" until FDA takes final action. (Orrick)
• April 16, 2026: FDA scheduled an advisory committee review. A Federal Register notice set a Pharmacy Compounding Advisory Committee (PCAC) meeting for July 23–24, 2026, to consider BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), epitalon and semax for the 503A bulks list. (91 FR 20465, Docket FDA-2025-N-6895)
• July 23–24, 2026: the PCAC recommended six of seven, against FDA staff's proposals. FDA's briefing materials proposed that none of the seven be added. The committee nonetheless recommended adding BPC-157, KPV, TB-500, MOTS-c, epitalon and semax, and recommended against emideltide. The recommendations are advisory, not binding. (FDA PCAC briefing document; McDermott Will & Schulte)
• October 14, 2026: an "interim access" policy went to the White House. FDA's "Interim Access Policy for Compounding Using Certain Peptides" (RIN 0910-ZD94) was received for OMB review on October 14, 2026, and is still pending. Its text has not been published. (Reginfo.gov; CNBC, Oct. 15, 2026)
• Enforcement against "research use only" sellers continued. FDA issued warning letters to online peptide sellers in 2026, and a federal court sentenced the owner of an online peptide business to 70 months in prison in July 2026. (FDA warning letter, Aug. 24, 2026; U.S. Attorney, N.D. Ind.)

Bottom line as of October 22, 2026: none of these peptides is on the 503A bulks list or in 503A Category 1, and FDA has not published a final rule or an interim policy covering them. (FDA 503A categories list, updated May 14, 2026)

A note on terminology: these are not DEA "schedules"

People often describe these changes as peptides "moving from Schedule 2 to Schedule 1." That mixes up two unrelated systems.

• DEA schedules (I–V) apply to controlled substances under the Controlled Substances Act, such as opioids, stimulants and anabolic steroids. We found none of the peptides in this guide on DEA's published list of controlled substances. (DEA, Controlled Substances – Alphabetical Order)
• FDA compounding "categories" (1, 2 and 3) are FDA's interim enforcement buckets for bulk ingredients that people have nominated for use in compounding. They decide whether FDA intends to take action against a pharmacy for compounding with an ingredient while FDA evaluates it. They are not drug approvals and they are not DEA schedules. (FDA 503A interim policy guidance, Jan. 2025)

The numbering also runs the other way. In FDA's system, Category 1 is the more permissive bucket and Category 2 is the restrictive one, while DEA's Schedule I is the most restrictive.

FDA compounding categories, explained

Section 503A pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act covers drugs compounded by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician. If the conditions of section 503A are met, the compounded drug is exempt from FDA's approval, current good manufacturing practice and certain labeling requirements. One condition is that each bulk ingredient must (1) meet a USP or NF monograph, (2) be a component of an FDA-approved drug, or (3) appear on the 503A bulks list that FDA sets by regulation. (91 FR 20465)

Most of the peptides discussed here meet none of those three. For example, FDA's briefing materials state that semax has no USP or NF monograph and is not a component of an approved drug. (FDA PCAC presentations, July 2026) That is why the bulks list and FDA's interim categories matter so much.

The interim categories (503A). While FDA evaluates nominated ingredients, it sorts them as follows (FDA 503A interim policy guidance; FDA 503A categories list):

Two features of the January 2025 guidance matter here. FDA said it does not intend to place substances nominated on or after January 7, 2025 into these categories. It also said substances outside Category 1 are not within the enforcement policy. (FDA 503A interim policy guidance)

Section 503B outsourcing facilities. Outsourcing facilities may compound from a bulk ingredient only if it appears on the 503B bulks list (ingredients for which there is a "clinical need") or if the finished drug is on FDA's drug shortage list. FDA has a parallel set of 503B interim categories. (FDA 503B bulks page) The July 2026 PCAC meeting considered the peptides only for the 503A list. (91 FR 20465)

Status of commonly discussed peptides (as of October 22, 2026)

"Withdrawn" below means the substance appears on FDA's safety-risks page under "Bulk drug substances nominated but withdrawn." That table still records FDA's stated safety concerns. None of the substances in this table is on the 503A bulks list or in 503A Category 1 unless the table says otherwise.

About the vote counts. The 2024 votes come from FDA's own minutes and transcript. When we last checked, FDA had not posted minutes for the July 2026 meeting, so the July tallies (Yes–No–Abstain) are as reported by McDermott Will & Schulte. CNN separately reported the 8–6 BPC-157 vote. (CNN, July 22, 2026) Confirm against FDA's minutes when they are posted.

Not covered above. FDA's list also shows other substances some clinics use with peptides, such as NAD, glutathione and vasoactive intestinal peptide, in 503A Category 1. (FDA categories list) Some peptides are components of FDA-approved drugs, which follow a different compounding pathway. That pathway is outside the scope of this guide, and status should be confirmed ingredient by ingredient.

What "doctor-prescribed BPC-157" means now

FDA has not approved BPC-157, and it is not yet compoundable under a clear federal pathway. As of October 22, 2026:

• BPC-157 is not an FDA-approved drug. FDA's July 2026 review states there is no USP drug substance monograph for BPC-157 (free base or acetate) and that neither is a component of an FDA-approved drug, so the bulks list is its only potential 503A route. FDA staff proposed against adding it. (FDA BPC-157 briefing; FDA PCAC briefing)
• It is not on the 503A bulks list and not in 503A Category 1, so the conditions of FDA's January 2025 enforcement-discretion policy are not met. (FDA categories list; FDA interim policy)
• It is no longer in active Category 2, but FDA's website still lists its safety concerns: possible immunogenicity, peptide impurities, and no or only limited safety information for the proposed routes of administration. (FDA safety page)
• The PCAC's July 23, 2026 recommendation does not change its legal status by itself. Formally adding a substance to the bulks list requires notice-and-comment rulemaking. (National Law Review; McDermott)

Some commentators expect FDA to exercise some informal enforcement discretion for the PCAC-recommended peptides in the interim. (McDermott) Expected discretion is not published policy, and it does not bind FDA or state boards. Other counsel advised in April that pharmacies should not begin compounding these peptides on the strength of the Category 2 removal alone. (Orrick)

If FDA does open a pathway, by adding BPC-157 to the bulks list or by issuing an interim policy, the conditions will depend on the final text. Based on section 503A and FDA's existing interim policy, operators should expect conditions like these:

1. A valid prescription for an identified individual patient from a licensed prescriber, following an appropriate clinical evaluation under the rules of the state where the patient is located.
2. Compounding by a state-licensed pharmacy (or licensed physician) operating under section 503A, not an outsourcing facility, unless the 503B rules separately allow it. (91 FR 20465)
3. Pharmaceutical-grade ingredient sourcing: bulk ingredient made by an FDA-registered establishment and accompanied by a valid certificate of analysis. (FDA interim policy)
4. Compliance with all other 503A conditions and with state pharmacy law, including any state rules stricter than federal law.
5. Any route, form or use limits in the final text. FDA evaluates free base and acetate forms separately, and its listings can be route-specific, as with GHK-Cu. (FDA BPC-157 briefing; FDA categories list)

Even then, a compounded BPC-157 product would not be an FDA-approved drug, and FDA would not have reviewed it for safety or effectiveness.

What's pending: watch list

• The interim access policy. It has been under OMB review since October 14, 2026, at the notice stage, with no legal deadline. Its covered peptides and conditions are not public. Press reports, citing unnamed sources, say it would use enforcement discretion to let pharmacies temporarily compound some peptides, including BPC-157. Treat that as unconfirmed until FDA publishes the text. (Reginfo.gov; CNBC)
• Rulemaking for the six PCAC-recommended peptides. FDA has not published a proposed rule that we could find. CNBC reported it was "not immediately clear" whether the administration still plans to pursue formal rulemaking. (CNBC)
• The next PCAC meeting, to be held before the end of February 2027, on GHK-Cu, Melanotan II, LL-37, dihexa acetate and PEG-MGF. Its date and Federal Register notice had not been published when we checked. (FDA PCAC meeting page)
• Official July 2026 minutes. These will confirm the vote counts.
• State action. State boards can be stricter than FDA, and some have already acted on peptides (see below).
• HHS direction. HHS Secretary Robert F. Kennedy Jr. said in February 2026 that the administration would act to make roughly 14 peptides more accessible through "ethical suppliers." Statements like this signal direction but are not law. (Orrick)

Operational implications for clinics, telehealth brands and MSOs

Each item below is a question to work through with healthcare counsel, your clinical leadership and your pharmacy partners, not a conclusion about what is permitted.

Pharmacy sourcing

• Work only with state-licensed 503A pharmacies, or registered 503B outsourcing facilities where the 503B rules allow it, that are licensed or permitted to ship to each patient's state.
• Ask each pharmacy, in writing, for its legal basis to compound each ingredient (monograph, approved-drug component, bulks list or Category 1), its API manufacturer's FDA registration, and certificates of analysis.
• Do not buy, stock or administer "research use only" products. Ohio's Board of Pharmacy says such products are unlawful for prescriber clinics and med spas to possess, regardless of patient consent, and that BPC-157 and other Category 2 and 3 substances cannot be compounded. That guidance is dated December 8, 2025, before FDA's April 2026 changes, so ask counsel how Ohio applies it now. (Ohio Board of Pharmacy) A June 2026 Alabama Medical Board notice reportedly says physicians may not compound, administer or dispense non-FDA-approved or research-grade peptides. (McDermott, Sept. 24, 2026)

Prescribing and clinical governance

• Prescribing decisions belong to licensed clinicians and the professional entity, not to the brand or MSO. Protocols, formularies and product menus should be set and owned clinically. See How the MSO/PC model works.
• Telehealth prescribing must satisfy the rules of each patient's state, including requirements for establishing a patient relationship. These vary and change.
• Avoid business arrangements in which the MSO, brand or pharmacy is paid according to prescription volume for a particular product without counsel review.

Marketing

• Do not describe compounded peptides as FDA-approved, "FDA-cleared" or "legal now," and do not suggest a regulatory step is final when it is not.
• Do not make safety or effectiveness claims about unapproved peptides. FDA's 2026 warning letters treated product descriptions such as "studied for" and "investigated for" as evidence of intended drug use, despite "research use only" labels. (FDA warning letter)
• Do not promote peptides that are not available through a compliant pathway, and do not offer waitlists or pre-sales that imply availability.
• Have counsel review where the brand, rather than the practice, advertises medical services. Some states limit this.

Informed consent and patient communication

• Consent materials, prepared by the clinical team with counsel, should state that the product is compounded, is not FDA-approved, and has not been reviewed by FDA for safety, effectiveness or quality. They should also cover any FDA-identified safety concerns and alternatives, including FDA-approved options where they exist.
• Athletes. WADA's 2026 Prohibited List names BPC-157 under S0 (non-approved substances, prohibited at all times). It lists TB-500 under thymosin-β4 derivatives (S2.3), and AOD-9604, CJC-1295 and ipamorelin under S2.2. Patients subject to anti-doping rules should be told. (WADA 2026 Prohibited List)

Enforcement exposure

• "Research use only" labels have not protected sellers. FDA found dosing guidance, injection instructions and dose calculators to be evidence of human use, and treated bacteriostatic water sold for reconstitution as an unapproved drug. (FDA warning letter; McDermott)
• Criminal cases are possible. On July 30, 2026, the owner of Paradigm Peptides was sentenced to 5 years and 10 months in federal prison, and an employee to 1 year and 4 months, after guilty pleas. The government said the business sold peptides, SARMs and hCG that were unapproved new drugs, and that some products labeled as SARMs contained testosterone. (U.S. Attorney, N.D. Ind.)
• In earlier litigation, two companies sued FDA over its 2023 Category 2 placements. The September 2024 settlement led to the October and December 2024 PCAC meetings, but no court ruling on the categories. (Alliance for Pharmacy Compounding)

Planning

• Prepare for both outcomes. If a pathway opens, operators will need pharmacy contracts, clinical protocols, consent forms and marketing review ready. If it does not, or if states restrict peptides further, avoid building revenue plans around products without a clear legal basis.
• Large telehealth companies have announced plans to offer peptides if federal access eases, so competition and regulatory attention may both rise. (CNBC)

How we help

We help operators with the business side of a pharmacy and prescribing program: mapping which decisions sit with the clinical entity and which with the MSO, building pharmacy diligence checklists, designing workflows around the patient's state, and organizing marketing review. We work alongside your healthcare and FDA counsel, not in place of them. Melius may have business relationships with pharmacies, telehealth platforms or clinical networks, and if we have a relationship with any vendor we discuss, we tell you. See how we engage or get in touch. For the pharmacy side of the stack, read Pharmacy integration for telehealth.

Frequently asked questions

Is BPC-157 FDA-approved now?

No. BPC-157 is not an FDA-approved drug. In 2026 it was removed from FDA's Category 2 list, and an FDA advisory committee recommended adding it to the 503A bulks list. As of October 22, 2026, FDA had not added it to the list, placed it in Category 1, or published a policy allowing it to be compounded.

Can a doctor prescribe BPC-157 and have a pharmacy compound it today?

There is no clear federal pathway yet, because BPC-157 is not on the 503A bulks list or in Category 1. Some state boards have said it cannot be compounded. Anyone considering it should get advice from healthcare and FDA counsel and confirm the pharmacy's written legal basis.

Did peptides move from "Schedule 2" to "Schedule 1"?

No. DEA schedules govern controlled substances. FDA's Categories 1–3 are compounding enforcement categories. Twelve peptides left FDA's Category 2 in April 2026 because their nominations were withdrawn. They did not move into Category 1, except non-injectable GHK-Cu, which FDA restored to Category 1 in May 2026.

What did the July 2026 advisory committee decide?

It recommended that FDA add BPC-157, KPV, TB-500, MOTS-c, epitalon and semax to the 503A bulks list, and recommended against emideltide (DSIP). FDA staff had proposed against all seven. The recommendations are advisory.

What is the "interim access policy"?

It is an FDA policy titled "Interim Access Policy for Compounding Using Certain Peptides," submitted for White House (OMB) review on October 14, 2026. Its text has not been published, so which peptides it covers and on what conditions is not yet known.

Can 503B outsourcing facilities make these peptides?

Outsourcing facilities generally need an ingredient to be on the 503B bulks list, or the finished drug to be in shortage. The July 2026 review concerned the 503A list only, and ipamorelin, GHRP-2 and GHRP-6 remain in 503B Category 2.

Are "research use only" peptides a legal alternative?

Regulators have treated RUO labels as no defense when products are sold for human use, and Ohio's pharmacy board says clinics may not possess them. Clinics should not purchase or administer RUO products.

Does any of this matter for athletes?

Yes. WADA's 2026 Prohibited List names BPC-157 and covers TB-500, CJC-1295, ipamorelin and AOD-9604, among others.